Recursion Pharmaceuticals' AI-based approach has the potential to transform the pharmaceutical industry. However, it is still chasing clinical wins that would demonstrate the power of its strategy.

Management believes it can drastically cut down the time and cost to bring drugs to market. The company is involved with multiple clinical trials, but none of them are in late stages just yet. Its ...

Recursion, Roche, and its Genentech subsidiary have unveiled the latest product of their nearly four-year artificial intelligence (AI) drug discovery collaboration, a whole-genome map of specialized ...

Welcome to this afternoon session with Recursion. My name is Andrew Pucher. I'm part of the Healthcare Investment Banking team, and I'm joined by Ben Taylor, CFO of Recursion; and Sara Sherman, Head ...

Automaker Stellantis and Massachusetts-based battery startup Factorial Energy have announced validation of a new solid-state electric vehicle battery that could be a game-changer for the industry.

Pipeline: Delivered on our commitment to a more focused R&D strategy by advancing a streamlined portfolio of 5+ clinical and preclinical programs in oncology and rare disease, while deprioritizing 3 ...

Semi-solid-state battery cells engineered by Factorial Energy complete successful validation test with automaker Stellantis. Factorial's FEST (Factorial Electrolyte System Technology) battery cells ...

I'm diving deep into the intersection of infrastructure and machine learning. I'm fascinated by exploring scalable architectures, MLOps, and the latest advancements in AI-driven systems ...

Investors looking for an exciting clinical-stage biotech start-up with enormous potential should be paying close attention to Recursion Pharmaceuticals (NASDAQ: RXRX). The company has emerged as a ...